Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, Barry M., Cooper, Mark E., de Zeeuw, Dick, Keane, William F., Mitch, William E., Parving, Hans-Henrik, Remuzzi, Giuseppe, Snapinn, Steven M. +2 more·2001·New England Journal of Medicine
DOI 10.1056/nejmoa011161

Cited by (7,499)

Items 6,501–6,600 of 7,499

  1. 2. Importance of Early Detection and Diagnosis for Kidney Diseases
    Yasuhiko Iino · 2005 · Internal Medicine
  2. Optimal renin-angiotensin-aldosterone system control—direct renin inhibitors beyond blood pressure reductions
    Sachin T Hundekari, Sujatha Shetty · 2011 · Journal of Indian College of Cardiology
  3. Ancient terms of chronic renal failure: The key to ancient literature mining
    Lei Zhang, Yin Li, Deli Zhu · 2013 · IEEE International Conference on Bioinformatics and Biomedicine (BIBM)
  4. L’hypertension artérielle du diabétique dans la « vraie vie » : d’une recommandation à l’autre… !
    B Chamontin, Béatrice Bouhanick, L. Perez · 2008 · Médecine des Maladies Métaboliques
  5. Introduction to Glycemia and Type 2 Diabetes with Epidemiology and Current Status of Persons with Type 2 Diabetes
    Zachary T. Bloomgarden · 2010 · Endocrine Practice
  6. Tratamiento de la hipertensión arterial
    Alejandro de la Sierra · 2006 · Hipertensión y Riesgo Vascular
  7. More on the LIFE study
    Steven M. Snapinn · 2003 · The Lancet
  8. The dual blockade of the renin-angiotensin system in Internal Medicine: after ONTARGET trial
    Francesco Rondoni, F. Rossetti · 2013 · Italian Journal of Medicine
  9. Olmesartan to Prevent the Development of Microalbuminuria: Is It New? Is It True? Is It Important?
    Jamie P. Dwyer, Julia Breyer Lewis · 2011 · American Journal of Kidney Diseases
  10. Therapy of chronic renal insufficiency: from renal physiology to cardiovascular outcomes
    Rainer Ullrich Pliquett · 2005 · Therapy
  11. Treating Patients for Cardiovascular Protection: Combination Therapy to Achieve Complete Renin‐Angiotensin System Blockade
    Alan H. Gradman · 2007 · Preventive Cardiology
  12. Cambios inducidos por la enfermedad renal crónica en los pacientes con diabetes
    José Luis Teruel, Sandra Beltrán Catalán · 2010 · Avances en Diabetología
  13. Klinische und gesundheitsökonomische Auswirkungen einer frühen Irbesartan-Therapie bei Typ-2-Diabetes, Hypertonie und Nierenerkrankung
    Andrew John Palmer, S Roze, Roger A. Rodby · 2006 · PharmacoEconomics German Research Articles
  14. World Kidney Day 2011: Protect Your Kidneys, Save Your Heart
    William G. Couser, Miguel Carlos RIELLA · 2011 · Kidney & Blood Pressure Research
  15. O acometimento renal na hipertensão arterial e diabetes mellitus tipo 2: como identificar e prevenir? – A visão do cardiologista
    Érika Maria Gonçalves Campana, Andréa Araújo Brandão · 2013 · Revista Hospital Universitário Pedro Ernesto
  16. Implicaciones del estudio ONTARGET en hipertensión arterial y diabetes tipo 2
    Mónica Doménech, António Coca · 2008 · Revista Española de Cardiología Suplementos
  17. Progression of Renal Failure Delayed by Use of Losartan in a Case of IgA Nephropathy.
    Kunitoshi Iseki, Shuichi Takishita · 2002 · Internal Medicine
  18. Secundaire en maligne hypertensiehypertensie
    Peter W. de Leeuw, prof.dr. W.H. Birkenhäger · 2003 · Bijblijven
  19. Diabetic Nephropathy: Prevention and Management
    Sai Prasad Sahoo, Sandeep Kumar Mandal, Sanjiv Jasuja · 2009 · Apollo Medicine
  20. [An analysis of chemical oxygen demand, carbohydrate, IgG and IgA in extracellular fluid of bacterial plaque].
    Y Mao, S Yue · 1991 · PubMed
  21. Inhibición directa de la renina y protección de órganos diana. Más allá del descenso de la presión
    Vicente Bertoméu, Mariano de la Figuera, Carlos Calvo · 2011 · Revista Española de Cardiología Suplementos
  22. Ralentir la progression de l’insuffisance rénale chronique : espoirs et déceptions. La réparation vasculaire du rein chronique
    Jean‐Jacques Boffa, Sophie Chauvet, Fabrice Mihout · 2011 · La Presse Médicale
  23. “Fere libenter homines id quod volunt credunt”: Apprehension for the stroke reduction in the KYOTO HEART Study on the basis of meta-regression from the evidence
    Hisato Takagi, Takuya Umemoto · 2013 · International Journal of Cardiology
  24. Proteinuria: pathophysiology, diagnostic and therapeutic approach
    Enrico V. Valvo · 2013 · Italian Journal of Medicine
  25. More Confusing Messages From the Hypertension Treatment Trials
    Marvin Moser · 2006 · Journal of Clinical Hypertension
  26. Mechanics or mediators: arterial damage from high blood pressure
    Graham J. Macdonald · 2006 · Journal of Hypertension
  27. Tratamiento de la hipertensión arterial con antagonistas de los receptores de la angiotensina II
    Manuel Gorostidi Pérez, R. Marín Iranzo · 2002 · Hipertensión y Riesgo Vascular
  28. Do Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Have Similar Effects in the Improvement of Left Ventricular Dysfunction after Myocardial Infarction in Japanese?
    Shin‐ichiro Miura, Keijiro Saku · 2009 · Internal Medicine
  29. Antiproteinuric Effect of Aliskiren versus Losartan in Primary Glomerulonephritis
    Abdul Halim Abdul Gafor, Azrini Abdul Aziz, Rozita Mohd · 2014 · Open Journal of Nephrology
  30. Roles of MEK/ERK Pathway in Vascular and Renal Tubular Actions of Angiotensin II
    George Seki, Hideomi Yamada, Yuehong Li · 2009 · Vascular Disease Prevention
  31. Antagonistas de los receptores de la angiotensina II en el tratamiento de la hipertensión arterial, las enfermedades cardiovasculares y las renales. Realidad y futuro
    Alejandro de la Sierra · 2013 · Hipertensión y Riesgo Vascular
  32. Managing Patients With Chronic Kidney Disease
    David G. Warnock · 2012 · Clinical Therapeutics
  33. Papel actual de los nuevos calcioantagonistas dihidropiridínicos en el tratamiento de la hipertensión arterial
    António Coca · 2003 · Anales de Medicina Interna
  34. The hidden cost of switching medication
    John Cannon · 2008 · British Journal of Healthcare Management
  35. Pediatric Nephrology: Highlights for the General Practitioner
    Mouin G. Seikaly, Sabeen Habib, Amin J. Barakat · 2012 · International Journal of Pediatrics
  36. Toward better renoprotection: Lessons from angiotensin receptor blockers
    Toshio Miyata, Shunya Takizawa · 2007 · Hemodialysis International
  37. Update Nephrologie¶Renoprotektion durch Antihypertensiva: Teil I
    Günter Stein, R Fünfstück, H Sperschneider · 2002 · Medizinische Klinik - Intensivmedizin und Notfallmedizin
  38. Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers
    Cristina Sierra, Alejandro de la Sierra · 2005 · Current Opinion in Internal Medicine
  39. ¿Es posible prevenir la nefropatía diabética? El estudio ROADMAP
    Josep Galcerán · 2011 · Hipertensión y Riesgo Vascular
  40. Current Controversies over the Management of Elderly Hypertension with Impaired Renal Function
    Moon‐Jae Kim · 2011 · Journal of the Korean Society of Hypertension
  41. Tratamiento de la dislipemia y la diabetes mellitus en pacientes con enfermedad renal crónica. Evidencias e implicaciones
    David J.A. Goldsmith · 2009 · Medicina Clínica
  42. Achieved vs Initial Blood Pressure in Predicting Renal Outcomes—Reply
    George L. Bakris · 2004 · Archives of Internal Medicine
  43. Rigenerazione e Proteinuria, Quando L'albumina Fa La Differenza
    Duccio Lombardi · 2014 · Giornale di Techniche Nefrologiche e Dialitiche
  44. What's new in … Diabetes treatment
    Seán F. Dinneen, Robert K. Semple · 2002 · Medicine
  45. Specificity of the Cardiocerebral-Event Reductions in the Kyoto Heart and Jikei Heart Study
    Takuya Umemoto · 2013 · International Journal of Cardiovascular Research
  46. Angiotensin-receptor blockade in renal disease: the hard issues
    Dominic A. Sica · 2004 · Expert Review of Cardiovascular Therapy
  47. Efectos renales de los antagonistas del calcio
    José Antonio García‐Donaire, César Cerezo, Luis Miguel Ruilope · 2009 · Hipertensión y Riesgo Vascular
  48. Resolving the mysteries of the renin-angiotensin system in diabetes
    Atsuhiro Ichihara · 2006 · Journal of the Renin-Angiotensin-Aldosterone System
  49. Halting Chronic Allograft Nephropathy – Do We Already Have the Drugs?
    Stephen H. Powis · 2003 · Nephron Clinical Practice
  50. The impact of the metabolic syndrome and parental risk factors in patients with type 1 diabetes
    Lena M. Thorn · 2009 · Työväentutkimus Vuosikirja
  51. Management of type 2 diabetes mellitus for general practitioners
    AM Klisiewicz, KRL Huddle · 2011 · Journal of Endocrinology Metabolism and Diabetes of South Africa
  52. L’hypertension chez les diabétiques de type 2: Mise à jour sur le traitement pharmacologique
    Norm R.C. Campbell, Richard E. Gilbert, Lawrence A. Leiter, Pierre M. Larochelle, Sheldon W. Tobe, Arun Chockalingam, Richard A. Ward, Dorothy Morris, Ross T. Tsuyuki, Stewart B. Harris · 2011 · Europe PMC (PubMed Central)
  53. Renal protective capacity of the angiotensin receptor antagonists
    Ronald D. Smith, Carlos Maria Ferrario · 2004 · Therapy
  54. Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Closer Look at Hyperkalemia
    Sungjin Chung, Cheol Whee Park · 2011 · The Korean Journal of Internal Medicine
  55. Response to Letter by Mysak et al
    Ralph L. Sacco, Larry B. Goldstein · 2006 · Stroke
  56. Innate immune system and adiponectin in diabetic nephropathy in type 1 diabetes
    Markku Saraheimo · 2009 · Työväentutkimus Vuosikirja
  57. Valoración de la terapia combinada de Enalapril con Irbesartán sobre la función renal en pacientes diabéticos tipo 2
    Andrea Rodríguez Hernández, Shunit Rosenkrantz Amón, Federico Jiménez Loría · 2007 · Revista Médica de la Universidad de Costa Rica
  58. Aggravation de l’insuffisance rénale chronique et de ses facteurs de risque : Résultats provisoires du programme ProFiL
    Sébastien Beaunoyer, Sébastien Dupuis, Ariane Dumoulin-Charette et al. · 2014 · Pharmactuel
  59. Factores de riesgo cardiovascular y tratamiento hipolipemiante en la enfermedad cerebrovascular, cardíaca y periférica
    Radka Ivanova Georgieva · 2007 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
  60. The Myth of Janus
    Massimo Volpe · 2009 · High Blood Pressure & Cardiovascular Prevention
  61. [Antihypertensive therapy and cardiovascular prevention. The role of angiotensin II receptor blockers].
    Paolo Verdecchia, Claudio Cavallini, Fabio Angeli · 2007 · PubMed
  62. Effect of the Location of Previous Atherosclerotic Disease on Prognosis in Diabetic Patients. The Barbanza Diabetes Study
    José Ramón González‐Juanatey, Lilián Grigorian-Shamagian, María A. Juiz-Crespo · 2008 · Revista Española de Cardiología (English Edition)
  63. Angiotensin II (AT1) Redeptor Antagonists, Diabetes, and Nephropathy
    Thomas D. Giles, Gary E. Sander · 2002 · The American Journal of Geriatric Cardiology
  64. Careful re-evaluation of the impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease
    Mingyang Li · 2011 · Nephrology Dialysis Transplantation
  65. Incertitude entourant les seuils de pression artérielle systolique chez les personnes diabétiques
    Michael Allen, Kim Kelly, Isobel Fleming · 2013 · Europe PMC (PubMed Central)
  66. Approach to arterial hypertension in patients with diabetes mellitus.
    Lea Smircic Duvnjak, Krishna MoHan-Sepuri, Nikica Car, Željko Metelko · 2004 · Diabetologia Croatica
  67. On the relevance of carnosine and carnosinase for the development of diabetic nephropathy
    Eva Riedl · 2011 · University of Groningen research database (University of Groningen / Centre for Information Technology)
  68. Indicaciones y uso clínico de los antagonistas de los receptores de la angiotensina II en la insuficiencia cardíaca
    José María Lobos Bejarano · 2005 · FMC - Formación Médica Continuada en Atención Primaria
  69. Validierung eines Urinproteom-Klassifikators zur Frühdiagnose der diabetischen Nephropathie
    Justyna Siwy · 2015 · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver
  70. Discontinuing or Switching Selective Serotonin-Reuptake Inhibitors
    Scott A. Bull, Enid M. Hunkeler, Janelle Y Lee, Clayton R. Rowland, Todd E Williamson, Joseph R Schwab, Stephen W. Hurt · 2002 · Annals of Pharmacotherapy
  71. Nephrin-associated molecules in human glomerular diseases
    Pekka Ihalmo · 2007 · Työväentutkimus Vuosikirja
  72. The effects of dietary supplementation with Gum arabicon blood pressure and renal function in subjects with Type 2diabetes mellitus
    David A. Glover · 2012
  73. Disease profile: diabetic nephropathy
    Reena J. Popat, Sui Phin Kon · 2012 · Journal of Renal Nursing
  74. Age and Sex Effects on the Single‐ and Multiple‐dose Safety and Pharmacokinetics of the New Rennin Inhibitor ACT ‐178882
    Dick E. de Vries, Hiddo J.L. Heerspink · 2013 · Cardiovascular Therapeutics
  75. Avaliação prognóstica em longo prazo de pacientes diabéticos portadores de insuficiência renal crônica leve a moderada e doença coronária multiarterial submetidos aos tratamentos clínico, cirúrgico ou angioplastia
    Eduardo Gomes Lima · 2014
  76. Losartan reduced strokes and new onset diabetes more than atenolol in essential hypertension
    David Blecker, Saul Blecker · 2002 · BMJ Evidence-Based Medicine
  77. Angiotensin Receptor Blockers for the Treatment of Hypertension in Children
    Albert P. Rocchini · 2010 · Clinical Pediatrics
  78. Diabetic glomerulopathy-natural history, intervention and prediction of complications
    Nina Perrin · 2008 · Figshare
  79. Protective Effects of Aliskiren, Enalapril and Valsartan on Hypertension Target Organs in Spontaneously Hypertensive Rats
    Kalina Gjorgjievska, Maja Slaninka-Miceska, Gordana Petruševska · 2011 · Macedonian Journal of Medical Sciences (University of Skopje)
  80. Microalbuminuria and Kidney Disease: An Evidence-based Perspective
    Rigas Kalaitzidis, Pranav Dalal, George L. Bakris · 2010 · Springer eBooks
  81. Bloqueo de la angiotensina II en el tratamiento de la hipertensión arterial de los pacientes con diabetes mellitus
    J.L. Tovar · 2003 · Hipertensión y Riesgo Vascular
  82. A Reversible Syndrome of Acute Renal Failure Associated with Renin-Angiotensin Inhibitor Drugs
    Anil Kumar Mandal · 2014 · Jaypee Brothers Medical Publishers (P) Ltd. eBooks
  83. Perspectivas futuras del tratamiento con antagonistas de los recepetores de la angiotensina
    Alejandro de la Sierra · 2007 · Hipertensión
  84. Os bloqueadores da angiotensina II aumentam a incidência de infarto do miocárdio?
    Jorge Ilha Guimarães · 2005 · Arquivos Brasileiros de Cardiologia
  85. Comment: renal protective effects of angiotensin receptor blockers
    Benjamin J Epstein · 2004 · Annals of Pharmacotherapy
  86. Infection in the newborn (comments on current literature)
    Sarah S. Long · 2003 · The Journal of Pediatrics
  87. SYMPOSIUM: RENAL ASPECTS OF CARDIOVASCULAR PHARMACOTHERAPY Treatment of Hypertension in Patients with Renal Disease
    Jay Garg, George L. Bakris · 2015
  88. Untersuchungen zum Stellenwert der Albuminurie in der Diagnostik und Prognose der Nephropathie beim niereninsuffizienten Typ 2 Diabetiker
    Til Leimbach · 2014 · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver
  89. Amlodipine and Losartan: Reaction to Comparison
    Gilbert W. Gleim · 2003 · Journal of Clinical Hypertension
  90. Review: Renovascular disease in diabetic patients
    Cathy Hay, Philip A. Kalra · 2002 · The British Journal of Diabetes
  91. RENAL TRANSPLANTATION IMPROVES CARDIAC FUNCTION
    Yoshiko Munehisa, Hiroyuki Watanabe, Shigenori Terata · 2009
  92. Losartan reduced cardiovascular morbidity and mortality more than atenolol in patients with diabetes and essential hypertension
    David Blecker · 2002 · BMJ Evidence-Based Medicine
  93. Commentary: Should BP targets be lower in diabetic patients with microalbuminuria or nephropathy?
    James D. Walker · 2003 · The British Journal of Diabetes
  94. The End of the Road for Dual Renin Angiotensin System Blockade in Diabetic Nephropathy: Which Way Now?
    Andrew Advani · 2014 · Canadian Journal of Diabetes
  95. Dual renin-angiotensin-aldosterone system inhibition: boon or bust?
    Sheldon Hirsch · 2010 · International Journal of Clinical Practice
  96. New oral agents for type 2 diabetes
    Andrew J. Krentz · 2007 · Clinical Medicine
  97. Initial Choice of Antihypertensive on Long-Term Cardiovascular Outcomes in CKD
    Adam T. Whaley‐Connell, James R. Sowers · 2012 · Clinical Journal of the American Society of Nephrology
  98. Odporúčania Európskej hypertenziologickej spoločnosti a Európskej kardiologickej spoločnosti pre rok 2003 v manažmente artériovej hypertenzie
    Alberto Zanchetti · 2004
  99. Fifty years of established diabetic nephropathy — a personal perspective
    J. S. Cameron · 2003 · The British Journal of Diabetes
  100. 2003 Canadian hypertension recommendations. It's not all old hat.
    Robert John Petrella · 2004 · PubMed